A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer
Authors
Keywords
-
Journal
CANCER
Volume 122, Issue 12, Pages 1897-1904
Publisher
Wiley
Online
2016-03-29
DOI
10.1002/cncr.29927
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer
- (2015) Franklin M. Chu et al. EUROPEAN JOURNAL OF CANCER
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer
- (2014) Arun A. Azad et al. INVESTIGATIONAL NEW DRUGS
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)
- (2013) Arnoud J. Templeton et al. EUROPEAN UROLOGY
- Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
- (2012) Mari Nakabayashi et al. BJU INTERNATIONAL
- Lipid Profiles and Risk of Breast and Ovarian Cancer in the Swedish AMORIS Study
- (2012) J. C. Melvin et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study
- (2011) Mieke Van Hemelrijck et al. INTERNATIONAL JOURNAL OF CANCER
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
- (2010) A Schayowitz et al. BRITISH JOURNAL OF CANCER
- Prostate cancer risk in the Swedish AMORIS study
- (2010) Mieke Van Hemelrijck et al. CANCER
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten-Deficient Mouse Model of Prostate Cancer
- (2009) W. Zhang et al. CANCER RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival
- (2008) Y Wang et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started